Avinash Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Avinash Kaur has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Wei Li
Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, USA
2 shared publications - Connor Costa
Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, Florida 33136, United States
1 shared publication David Broyles
Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, Florida 33136, United States
1 shared publication- Dinesh Kalyanasundaram
Centre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi, 110016, India
1 shared publication - Emre Dikici
Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
1 shared publication Hong Tian
Everglades Biopharma, LLC Houston Texas USA
1 shared publication
Latest Publications
- Open Access
- 27 June 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 727, 150321
A method for rapid and reliable quantification of VEGF-cell binding activity
- 27 June 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 727, 150321
Open AccessA method for rapid and reliable quantification of VEGF-cell binding activity
- 30 December 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (5) , 2485-2492
Monitoring Pathogenic Viable E. coli O157:H7 in Food Matrices Based on the Detection of RNA Using Isothermal Amplification and a Paper-Based Platform
In recent years, the number of product recalls and contamination incidents involving pathogenic bacteria has significantly increased, and the ensuing infections continue to be an ongoing problem for public health and agriculture. Due to the widespread impact of these pathogens, there is a critical need for rapid, on-site assays that can provide rapid results. In this work, we demonstrate the development of a rapid and simple test based on the combination of reverse transcription with recombinase polymerase amplification followed by lateral flow strip detection of viable Escherichia coli O157:H7 cells by detecting the RNA of the pathogen. The optimized method can be performed for approximately 2 h with a detection limit of 10 CFU/mL of E. coli O157:H7 in buffer, spinach, and ground beef samples. Our assay is sensitive, detecting only E. coli O157:H7 and not nonpathogenic E. coli or other similar pathogens. This strategy was able to distinguish viable from nonviable bacteria and more significantly was able to detect viable but nonculturable bacteria, which is a major issue when using culture-based methods for monitoring pathogenic bacteria. An important advantage of this test is that it can provide timely identification and removal of contaminated consumables prior to distribution without an extensive sample preparation.
- 30 December 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (5) , 2485-2492
Monitoring Pathogenic Viable E. coli O157:H7 in Food Matrices Based on the Detection of RNA Using Isothermal Amplification and a Paper-Based Platform
In recent years, the number of product recalls and contamination incidents involving pathogenic bacteria has significantly increased, and the ensuing infections continue to be an ongoing problem for public health and agriculture. Due to the widespread impact of these pathogens, there is a critical need for rapid, on-site assays that can provide rapid results. In this work, we demonstrate the development of a rapid and simple test based on the combination of reverse transcription with recombinase polymerase amplification followed by lateral flow strip detection of viable Escherichia coli O157:H7 cells by detecting the RNA of the pathogen. The optimized method can be performed for approximately 2 h with a detection limit of 10 CFU/mL of E. coli O157:H7 in buffer, spinach, and ground beef samples. Our assay is sensitive, detecting only E. coli O157:H7 and not nonpathogenic E. coli or other similar pathogens. This strategy was able to distinguish viable from nonviable bacteria and more significantly was able to detect viable but nonculturable bacteria, which is a major issue when using culture-based methods for monitoring pathogenic bacteria. An important advantage of this test is that it can provide timely identification and removal of contaminated consumables prior to distribution without an extensive sample preparation.
- 17 December 2021
- Published by Wiley in The FASEB Journal
- Vol. 36 (1) , e22106
Selectively targeting disease‐restricted secretogranin III to alleviate choroidal neovascularization
Choroidal neovascularization (CNV), a leading cause of blindness in the elderly, is routinely treated with vascular endothelial growth factor (VEGF) inhibitors that have limited efficacy and potentially adverse side effects. An unmet clinical need is to develop novel therapies against other angiogenic factors for alternative or combination treatment to improve efficacy and safety. We recently described secretogranin III (Scg3) as a disease‐selective angiogenic factor, causally linked to diabetic retinopathy and acting independently of the VEGF pathway. An important question is whether such a disease‐selective Scg3 pathway contributes to other states of pathological angiogenesis beyond diabetic retinopathy. By applying a novel in vivo endothelial ligand binding assay, we found that the binding of Scg3 to CNV vessels in live mice was markedly increased over background binding to healthy choriocapillaris and blocked by an Scg3‐neutralizing antibody, whereas VEGF showed no such differential binding. Intravitreal injection of anti‐Scg3 humanized antibody Fab (hFab) inhibited Matrigel‐induced CNV with similar efficacy to the anti‐VEGF drug aflibercept. Importantly, a combination of anti‐Scg3 hFab and aflibercept synergistically alleviated CNV. Homozygous deletion of the Scg3 gene markedly reduced CNV severity and abolished the therapeutic activity of anti‐Scg3 hFab, but not aflibercept, suggesting a role for Scg3 in VEGF‐independent CNV pathogenesis and therapy. Our work demonstrates the stringent disease selectivity of Scg3 binding and positions anti‐Scg3 hFab as a next‐generation disease‐targeted anti‐angiogenic therapy for CNV.
- 17 December 2021
- Published by Wiley in The FASEB Journal
- Vol. 36 (1) , e22106
Selectively targeting disease‐restricted secretogranin III to alleviate choroidal neovascularization
Choroidal neovascularization (CNV), a leading cause of blindness in the elderly, is routinely treated with vascular endothelial growth factor (VEGF) inhibitors that have limited efficacy and potentially adverse side effects. An unmet clinical need is to develop novel therapies against other angiogenic factors for alternative or combination treatment to improve efficacy and safety. We recently described secretogranin III (Scg3) as a disease‐selective angiogenic factor, causally linked to diabetic retinopathy and acting independently of the VEGF pathway. An important question is whether such a disease‐selective Scg3 pathway contributes to other states of pathological angiogenesis beyond diabetic retinopathy. By applying a novel in vivo endothelial ligand binding assay, we found that the binding of Scg3 to CNV vessels in live mice was markedly increased over background binding to healthy choriocapillaris and blocked by an Scg3‐neutralizing antibody, whereas VEGF showed no such differential binding. Intravitreal injection of anti‐Scg3 humanized antibody Fab (hFab) inhibited Matrigel‐induced CNV with similar efficacy to the anti‐VEGF drug aflibercept. Importantly, a combination of anti‐Scg3 hFab and aflibercept synergistically alleviated CNV. Homozygous deletion of the Scg3 gene markedly reduced CNV severity and abolished the therapeutic activity of anti‐Scg3 hFab, but not aflibercept, suggesting a role for Scg3 in VEGF‐independent CNV pathogenesis and therapy. Our work demonstrates the stringent disease selectivity of Scg3 binding and positions anti‐Scg3 hFab as a next‐generation disease‐targeted anti‐angiogenic therapy for CNV.
- Open Access
- 1 April 2020
- Published by Elsevier in Journal of Oral Biology and Craniofacial Research
- Vol. 10 (2) , 93-98
Levels of TGF-β1 in peri-miniscrew implant crevicular fluid
- 1 April 2020
- Published by Elsevier in Journal of Oral Biology and Craniofacial Research
- Vol. 10 (2) , 93-98
Open AccessLevels of TGF-β1 in peri-miniscrew implant crevicular fluid